Results 11 to 20 of about 19,378,005 (296)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T) [PDF]

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2021
Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-T to treat multiple myeloma and other hematological malignancies.
Galli, Eugenio   +10 more
openaire   +6 more sources

Chimeric Antigen Receptor T Cell Therapy in Hematology

open access: yesTurkish Journal of Hematology, 2015
It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell ...
Pınar Ataca, Önder Arslan
doaj   +3 more sources

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

open access: yesCells, 2023
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with
Bryanna Reinhardt   +2 more
doaj   +3 more sources

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas [PDF]

open access: yesFrontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell ...
Bei Hu   +3 more
doaj   +2 more sources

Chimeric antigen receptor T cell

open access: yesIndian Journal of Pharmacology, 2022
During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and ...
Singh, Surjit   +4 more
openaire   +2 more sources

Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic [PDF]

open access: yes, 2021
Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this ...
Caitlin R Hopkins, Joseph A Fraietta
core   +1 more source

[Chimeric antigen receptor T cells].

open access: yesBulletin du cancer, 2021
Chimeric antigen receptor T-cell (CAR T-cells) therapies which are genetically modified T lymphocyte targeting tumor antigens have modified therapeutic landscape in hematology. Aggressive B cells lymphoma are currently treated in daily practice with anti-CD19 CAR T.
Bories, Pierre, Ysebaert, Loïc
openaire   +2 more sources

Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure

open access: yesTransplantation and Cellular Therapy, 2023
Outcomes for post-chimeric antigen receptor (CAR) T cell therapy (CART) relapse are poor. The utilization of a unique CAR T cell construct for post-CART failure is increasing, but this approach is not well described. In this study, with CART-A the first unique CAR T cell construct received and CART-B the second, the primary objective was to ...
Elizabeth M. Holland   +15 more
openaire   +2 more sources

Experimental and Clinical Pharmacology: Chimeric antigen receptor T-cell therapy

open access: yesAustralian Prescriber, 2023
Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission.
Burge, Cale   +2 more
openaire   +2 more sources

Chimeric Antigen Receptors for T-Cell Malignancies [PDF]

open access: yesFrontiers in Oncology, 2019
Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells.
Lauren D. Scherer   +8 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy